H.B. Fuller Company (FUL) Q3 2026 earnings summary
Event summary combining transcript, slides, and related documents.
Q3 2026 earnings summary
24 Sep, 2026Executive summary
Q3 2026 net revenue increased 5.2% year-over-year to $938 million, with organic revenue up 4.4% and growth across all business units, driven by higher product pricing and positive currency effects, partially offset by lower volumes.
Adjusted EBITDA rose 9% year-over-year to $187 million, with a record margin of 19.9%, and adjusted EPS (diluted) increased 21% to $1.52.
Net income for Q3 was $79.2 million, up from $67.2 million in Q3 2025.
Pricing actions and restructuring offset higher raw material costs and supply chain disruptions.
AMS acquisition expected to close by year-end, strengthening the portfolio and supporting long-term growth.
Financial highlights
Q3 2026 net revenue: $938.2 million (up 5.2% year-over-year); organic revenue up 4.4%; adjusted EBITDA $187 million (19.9% margin); adjusted EPS $1.52 (up 21%).
Adjusted gross profit margin rose 120 basis points to 33.5%.
Year-to-date cash flow from operations was $183 million, up 17% year-over-year.
Net working capital at 18.5% of annualized net revenue, up 150 basis points year-over-year due to inventory investments.
Net debt-to-adjusted EBITDA improved to 3.0x from 3.3x a year ago.
Outlook and guidance
Fiscal 2026 net revenue expected up mid-single digits; organic revenue up low-single digits; adjusted EBITDA guidance: $655M–$670M; adjusted EPS: $4.70–$4.85.
Cash flow from operations (excluding AMS): $300M–$325M.
Core tax rate forecasted at 25.5%–26.0%.
AMS acquisition to close by year-end; leverage expected to return to 2.5x–3.0x within two years post-close.
Management expects restructuring costs to continue into fiscal 2027, with most charges and cash payments in 2026 and 2027.
Latest events from H.B. Fuller Company
- Acquisition accelerates medical growth, expands TAM to ~$95B, and targets $55M in synergies.FUL
Acquisition presentation - Q2 2026 saw strong revenue, margin, and EPS growth, with a major medical acquisition announced.FUL
Q2 2026 - All proposals passed, including director elections and auditor ratification, with no shareholder questions.FUL
AGM 2026 - Adjusted EBITDA and EPS rose with margin expansion despite a 6.6% organic revenue decline.FUL
Q1 2026 - Proxy covers director elections, auditor ratification, pay, strong results, and ESG focus.FUL
Proxy Filing - Votes will be cast for director elections, auditor ratification, and executive pay approval.FUL
Proxy Filing - Adjusted EBITDA and EPS grew 5% year-over-year, with margin gains and raised full-year guidance.FUL
Q2 2025 - Q3 2024 saw 6% EBITDA and 7% EPS growth, led by strong Construction Adhesives results.FUL
Q3 2024 - Adjusted EPS up 20% and EBITDA up 10% year-over-year, with 2024 guidance raised.FUL
Q2 2024